Jaguar Health 
Welcome,         Profile    Billing    Logout  
 1 Product   17 Diseases  1 Product   3 Trials   155 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mytesi (crofelemer) / Jaguar Health, Knight Therap
NCT03898856: Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients

Recruiting
4
100
US
Crofelemer, Diagnostic tests for cause of chronic diarrhea
The University of Texas Health Science Center, Houston, Napo Pharmaceuticals, Inc.
Chronic Diarrhea of Unknown Origin
10/24
12/24
OnTARGET, NCT04538625: Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

Completed
3
287
US, RoW
Crofelemer 125 MG [Mytesi], Placebo
Napo Pharmaceuticals, Inc.
Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea
08/23
10/23
NCT06721871: Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)

Not yet recruiting
2
12
Europe, US, RoW
Crofelemer Powder for Oral Solution, Placebo Powder for Oral Solution
Napo Pharmaceuticals, Inc.
Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases
12/25
03/26
NCT06326645: Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

Not yet recruiting
1
6
US
Crofelemer Oral Product
Lindsey Russell, MD, Napo Pharmaceuticals, Inc.
Short Bowel Syndrome
12/25
12/25
NCT05804396: Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for Preventive Treatment of Migraine

Withdrawn
N/A
57
NA
Relivion®
Neurolief Ltd.
Migraine
11/24
11/24

Download Options